Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of geldanamycin analogue (17-AAG) for advanced cancer
This trial was looking at a new chemotherapy drug called geldanamycin analogue (17-AAG) for advanced cancer. This trial was supported by Cancer Research UK..
Doctors sometimes use chemotherapy to control the symptoms of
The aims of the trial were to
- Find a safe a dose of the drug to use
- Learn more about the side effects
- See if the drug helped people with advanced cancer
Summary of results
The researchers found a safe dose of 17-AAG that didn’t cause too many side effects. But the cancer did not get smaller in any of the people in this trial.
- 30 people had treatment as part of this trial
- 11 people had melanoma
- The rest had other types of cancer including
sarcoma, breast cancer, bowel cancer and mesothelioma.
The first few patients had a very low dose of 17-AAG. As they didn’t have any bad side effects, the next few people had a higher dose, and so on. At least 3 people safely had each dose before the dose was increased. By doing this, the researchers were able to work out the highest dose they could use without causing bad side effects.
The researchers also looked at the effect 17-AAG had on advanced cancer. In most people, they could not see a response to the drug. But in 2 people who had melanoma, the cancer stayed the same size – researchers call this
As 17-AAG helped these 2 people and a safe dose has been worked out, the researchers suggested it should be studied in further trials.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Prof Ian Judson
Cancer Research UK (Centre for Drug Development)
This is Cancer Research UK trial number CRUKD/99/013.